Clinical Trial Update: Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study [NA]

View source ↗

Summary

A Phase II trial is evaluating a double-dose third-generation EGFR-TKI combined with bevacizumab and intrathecal chemotherapy for leptomeningeal metastasis in n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptomeningeal Metastasis
• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Intrathecal chemotherapy
• Third-generation EGFR-TKI (double-dose)

Snippet

Sponsor: Second Affiliated Hospital of Nanchang University | Conditions: Leptomeningeal Metastasis, Lung Neoplasms, Non-Small Cell Lung Cancer | NA | Status: RECRUITING